TTPH - テトラフェ―ズ・ファ―マシュ―ティカルズ (Tetraphase Pharmaceuticals Inc.)

TTPHのニュース

   Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home  2020/06/29 11:16:43 Seeking Alpha
Merger activity decreased last week with one new deal announced. Tetraphase Pharmaceuticals agreed to be acquired by La Jolla Pharmaceutical Company. Waste Mana
   La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.  2020/06/24 11:30:00 GlobeNewswire
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value…
   La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer  2020/06/22 16:14:54 Benzinga
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com
   The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset  2020/06/10 11:30:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Imara Inc (NASDAQ: IMRA ) IMMURON LTD/S ADR (NASDAQ: IMRN )( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea) Inari Medical Inc (NASDAQ: NARI ) Keros Therapeutics Inc (NASDAQ: KROS ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) United Therapeutics Corporation (NASDAQ: UTHR ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 9) Applied Molecular Transport Inc (NASDAQ: AMTI ) (IPOed Friday) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Stocks In Focus Melinta Agrees To Take Tetraphase Private For $39M In Cash And $16M In CVRs With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.
   Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals  2020/06/04 13:22:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced that it has entered into a definitive merger agreement with Melinta Therapeutics, Inc. (“Melinta”), pursuant to which Melinta would acquire Tetraphase, through a tender offer, for an aggregate of $39.0 million in cash, plus an additional $16.0 million in cash pot
   Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home  2020/06/29 11:16:43 Seeking Alpha
Merger activity decreased last week with one new deal announced. Tetraphase Pharmaceuticals agreed to be acquired by La Jolla Pharmaceutical Company. Waste Mana
   La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.  2020/06/24 11:30:00 GlobeNewswire
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value…
   La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer  2020/06/22 16:14:54 Benzinga
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com
   The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset  2020/06/10 11:30:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Imara Inc (NASDAQ: IMRA ) IMMURON LTD/S ADR (NASDAQ: IMRN )( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea) Inari Medical Inc (NASDAQ: NARI ) Keros Therapeutics Inc (NASDAQ: KROS ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) United Therapeutics Corporation (NASDAQ: UTHR ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 9) Applied Molecular Transport Inc (NASDAQ: AMTI ) (IPOed Friday) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Stocks In Focus Melinta Agrees To Take Tetraphase Private For $39M In Cash And $16M In CVRs With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.
   Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals  2020/06/04 13:22:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced that it has entered into a definitive merger agreement with Melinta Therapeutics, Inc. (“Melinta”), pursuant to which Melinta would acquire Tetraphase, through a tender offer, for an aggregate of $39.0 million in cash, plus an additional $16.0 million in cash pot
   Merger Arbitrage Mondays - Tetraphase Pharmaceuticals Finds A New Home  2020/06/29 11:16:43 Seeking Alpha
Merger activity decreased last week with one new deal announced. Tetraphase Pharmaceuticals agreed to be acquired by La Jolla Pharmaceutical Company. Waste Mana
   La Jolla Pharmaceutical Company to Acquire Tetraphase Pharmaceuticals, Inc.  2020/06/24 11:30:00 GlobeNewswire
La Jolla agreement provides for $43.0 million in upfront cash plus potential future cash payments of up to $16.0 million pursuant to contingent value…
   La Jolla Pharmaceutical Rekindles Interest In Tetraphase With Sweetened Offer  2020/06/22 16:14:54 Benzinga
The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) seems to be far from over. What Happened: Tetraphase announced Monday that La Jolla Pharmaceutical Company (NASDAQ: LJPC ) has approached the company with an unsolicited acquisition proposal for $43 million in cash, plus an additional aggregate amount of $16 million in cash, potentially payable under contingent value rights issued in the transaction. Tetraphase markets Xerava, an antibiotic for treating complicated intra-abdominal infections. After Tetraphase signed an agreement to be acquired by AcelRx Pharmaceuticals … Full story available on Benzinga.com
   The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset  2020/06/10 11:30:59 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Imara Inc (NASDAQ: IMRA ) IMMURON LTD/S ADR (NASDAQ: IMRN )( reacted to an award of a $3.7 million in DoD funding for a new candidate that offers protection against travelers' diarrhea) Inari Medical Inc (NASDAQ: NARI ) Keros Therapeutics Inc (NASDAQ: KROS ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Sarepta Therapeutics Inc (NASDAQ: SRPT ) United Therapeutics Corporation (NASDAQ: UTHR ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 9) Applied Molecular Transport Inc (NASDAQ: AMTI ) (IPOed Friday) Ayala Pharmaceuticals Inc (NASDAQ: AYLA ) Stocks In Focus Melinta Agrees To Take Tetraphase Private For $39M In Cash And $16M In CVRs With the two-way contest for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) ending after AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) pulled out, Melinta announced a definitive merger agreement to acquire Tetraphase, through a tender offer, for an aggregate of $39 million in cash, plus an additional $16 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.
   Melinta Therapeutics to Acquire Tetraphase Pharmaceuticals  2020/06/04 13:22:00 Business Wire
WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ to treat serious and life-threatening infections, today announced that it has entered into a definitive merger agreement with Melinta Therapeutics, Inc. (“Melinta”), pursuant to which Melinta would acquire Tetraphase, through a tender offer, for an aggregate of $39.0 million in cash, plus an additional $16.0 million in cash pot

calendar